信立泰：关于泰卡西单抗注射液（SAL003）上市申请获得受理的公告

Core Viewpoint - Recently, the company announced that its self-developed Class 1 biological drug "Tykacizumab Injection" (Project Code: SAL003) has had its application for market approval accepted by the National Medical Products Administration [1] Group 1 - The company, Xinlitai, and its subsidiary, Xinlitai (Suzhou) Pharmaceutical Co., Ltd., are involved in the research and development of the drug [1]